Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Lisa Jarvis: At last, a simple strategy for COVID booster shots

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.

Tribune News Service

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

US buying $1.7 billion of Moderna’s omicron-specific booster

Moderna Inc. said it secured a $1.74 billion contract to supply the U.S. government with its new omicron-specific vaccine.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

This Is What Whales Are Betting On Moderna

Benzinga

Should you wait for the omicron booster? Why experts say you should 'get it now!'

If you're like most Americans, you've gotten your primary doses of a COVID-19 vaccine, but you haven't gotten the recommended booster shots. So if it's been several months since your last primary dose, you're probably due for a booster.

Los Angeles Times

Boost now or wait? Many wonder how best to ride out COVID's next wave

Gwyneth Paige didn’t want to get vaccinated against COVID-19 at first. With her health issues — hypertension, fibromyalgia, asthma — she wanted to see how other people fared after the shots. Then her mother got colon cancer.

Tribune News Service

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab

Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei

Benzinga

Get fourth COVID booster now, or wait? CDC says get the shot now, but many hesitate

About 70% of Americans 50 and older who got a first booster shot — and nearly as many of those 65 and older — haven’t gotten their second booster dose, the CDC says.

Chicago Sun-Times

COVID-19 vaccine Moderna is provisionally approved for kids under 5. This is what we know

Australian children aged six months to five years could soon be rolling up their sleeves for a COVID-19 jab. Here's what parents need to know.

ABC News

Novavax COVID shot for adults gains CDC advisers’ backing

Novavax Inc.’s shares surged after its COVID-19 vaccine won backing from a panel of U.S. public health advisers, a crucial step in providing officials with another tool against the virus as cases start to rise again.

Tribune News Service

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 23 strange trades.

Benzinga

Covid vaccine provisionally approved in Australia for children aged six months to six years

Moderna’s paediatric dose will become available only after Australian Technical Advisory Group on Immunisation gives advice

The Guardian - AU

Check Out What Whales Are Doing With MRNA

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

A dire moment in the pandemic ... was the chance he'd been waiting for

How Sotiris Missailidis, head of R&D in Brazil's vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

The Independent UK

Covid vaccine protection ‘short lived,’ booster doses essential, study confirms

‘Continual updating of our vaccinations and booster shots is critical,’ scientists say

ABC News

Australia has ordered millions more COVID vaccines than it needs. What are the options to deal with them?

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

Benzinga

Here's How To Trade This Pattern On BlackBerry, Moderna And Palantir Stocks

BlackBerry Ltd (NYSE: BB), Moderna Inc (NASDAQ: MRNA) and Palantir Technologies Inc (NYSE: PLTR) have been showing strength in

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

ABC News

COVID-19 vaccines targeting the Omicron variant are on the way — but it could be worth getting a fourth dose now

Omicron is now the dominant strain of COVID-19 around the world and boosters targeting this variant are getting closer to being released.

360info

The public deserves a return on the medicines governments support

Public money directly and indirectly supports pharmaceutical innovation. Governments need to ensure the public gets a fair return on its investment.

Tribune News Service

Novavax’s COVID vaccine gets US nod as latest pandemic weapon

Novavax Inc.’s COVID-19 vaccine was cleared by U.S. regulators, giving Americans another tool against the virus as cases start to rise again.

WEKU

These Brazilian besties are inventing an mRNA vaccine as a gift to the world

Pfizer and Moderna have refused to divulge details of how to make their cutting-edge COVID shots. Here's what two scientists — and longtime best friends — are doing about it.

Investors Business Daily

The Good News For Moderna's Covid Shot Wasn't Good News For Its Stock

Moderna stock fell Tuesday after the company said its omicron-targeting booster generated antibodies capable of tackling new variants.

Investors Business Daily

Will Novavax's Covid Booster Thesis Play Out? What The Survey Says

Novavax's Covid booster is preemptively gaining steam, according to the July IBD/TIPP Poll. The results come as NVAX stock climbs.

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.